Idera stock sinks on psoriasis drug examination setback Boston Business writing Idera Pharmaceuticals (Nasdaq: IDRA) saw its stock season more than 5 percent, Thursday, after the establishment announced that a planned Phase 2 study for a potential treatment for psoriasis had been option on clinical hold by the US Food and Drug ... Idera Reports Clinical Hold on planned Phase 2 Clinical legal proceeding of IMO-3100 PipelineReview.com (press release) all 2 tidings articles » Link To Article
No comments:
Post a Comment